Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies that target STAT3. The company aims to address significant unmet medical needs in fibrosis-driven, inflammatory, and proliferative diseases. Its product pipeline includes therapies for conditions such as liver cancer and idiopathic pulmonary fibrosis (IPF). Tvardi operates primarily in the biopharmaceutical sector, conducting clinical trials to advance its therapeutic candidates.
- Website
- tvarditherapeutics.com
- Issuer profile
- All listings